指南与共识银屑病与炎症性皮肤病皮肤感染

银屑病生物及非生物靶向治疗在潜伏结核感染或结核病进展风险患者中的管理:SPIN-FRT专家共识建议

Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2024-08-16

结核分枝杆菌感染后可呈潜伏状态,免疫抑制时可能激活。TNF抑制剂增加潜伏结核再激活风险,国际指南建议治疗前筛查并预防性治疗,该建议以谨慎原则扩展至IL-12/23、IL-17、IL-23和TYK2抑制剂。本文通过文献检索评估这些创新疗法相关的结核再激活风险,整合随机临床试验和真实世界证据,由SPIN-FRT专家组制定共识建议,强调需更新现有指南以提供更差异化的管理策略。

要点

  • TNF抑制剂与潜伏结核再激活风险显著增加相关,治疗前应筛查并预防性治疗。
  • IL-17和IL-23抑制剂再激活病例数少,提示需重新考虑所有潜伏结核患者均预防性治疗的必要性。
  • 共识建议强调需更新现有指南,基于生物制剂类别和患者个体风险制定差异化方案。

核心结论

  • 现有证据有限,但IL-17和IL-23抑制剂再激活病例数少,提示需重新考虑对所有潜伏结核患者无论生物制剂类别或个体风险均进行预防性治疗的必要性。
  • 共识建议强调需更新现有指南,以提供更差异化的方法,反映银屑病治疗演变及其对结核管理的影响。

研究设计与样本

  • 文献检索评估创新疗法相关的结核再激活风险,整合随机临床试验和真实世界证据。
  • 由SPIN-FRT专家组基于文献综述和临床见解制定共识建议。

主要发现

  • TNF抑制剂与潜伏结核再激活风险显著增加相关。
  • IL-17和IL-23抑制剂再激活病例数少。
  • 证据有限,但提示部分药物可能不与结核再激活或感染后结核病发展风险增加相关。

关键数值与推荐

  • 国际指南推荐在开始抗TNF治疗前进行结核筛查和预防性治疗。
  • 这些建议以谨慎原则扩展至IL-12/23、IL-17、IL-23和TYK2抑制剂,尽管作用机制不同。

临床怎么用

  • 对接受或计划接受生物及非生物靶向治疗的银屑病合并潜伏结核感染或结核感染风险患者,应基于药物类别和个体风险差异化评估预防性治疗必要性。
  • 临床需更新现有指南,采用更差异化的方法管理结核风险。

局限性

  • 识别的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a significant global health problem. In immunocompetent individuals, the microorganism can remain in a latent, non-contagious form, however, it may become active under conditions of immunosuppression. Tumour necrosis factor (TNF) inhibitors, which are frequently used for the management of immune-mediated disorders like psoriasis, have been associated with a significantly increased risk of reactivating latent TB. Consequently, international guidelines recommend TB screening and preventive treatment before starting anti-TNF therapy. These recommendations have extended to IL-12/23, IL-17, IL-23 and TYK2 inhibitors under a caution principle, despite their different mechanisms of action. However, current evidence suggests that some of these agents are arguably not associated with an increased risk of TB reactivation or development of TB disease after infection, which calls for a critical reassessment of these guidelines. We have conducted a literature search evaluating the risk of TB reactivation associated with these innovative therapies, integrating findings from both randomized clinical trials and real-world evidence. The identified evidence is limited but the low number of identified cases of reactivation with IL-17 and IL-23 inhibitors prompts reconsidering the need for preventive treatment for latent TB in all cases, regardless of biologic class or individual patient's risk of TB reactivation or drug toxicity. This review, along with the clinical insight of a panel of experts on behalf of the SPIN-FRT, led to the development of these consensus recommendations for managing psoriasis treatment in patients with latent TB infection or at risk of TB infection, who are receiving or are intended to receive biologic and non-biologic targeted therapies. These recommendations highlight the need for updates to the existing guidelines, aiming to provide a more differentiated approach that reflects the evolving landscape of psoriasis treatment and its implications for TB management.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Torres T, Brembilla NC, Langley RG, et al. Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus. J Eur Acad Dermatol Venereol. 2024. PMID: 39149807. doi:10.1111/jdv.20287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。